CU
CUE.US Cue Biopharma
- Market cap
- USD 117M
- P/E
- -
- P/B
- 55.01x
- ROE
- -13,700.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CUE.US undervalued?
Graham numberThe Graham number of Cue Biopharma cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cue Biopharma fundamental analysis
No fundamental analysis for Cue Biopharma yet.
Cue Biopharma stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-…
Full company profileCue Biopharma financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cue Biopharma annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 1.14M | 3.46M | 3.15M | 14.9M | 1.25M | 5.49M | 9.29M | 27.5M | 27.1M |
| Gross Profit | -202K | -420K | -27.4M | 3.46M | -30.4M | 14.9M | 1.25M | -32.6M | 9.29M | 27.5M | 27.1M |
| Operating Income | -7.66M | -23.2M | -38.7M | -36.8M | -45.0M | -43.7M | -53.2M | -52.1M | -41.5M | -26.5M | -186M |
| EBITDA | -7.46M | -22.8M | -37.9M | -31.6M | -44.0M | -45.5M | -50.5M | -46.1M | -37.5M | -24.8M | -185M |
| Net Income | -7.66M | -23.2M | -39.0M | -36.7M | -44.8M | -44.2M | -53.0M | -50.7M | -40.7M | -26.6M | -316M |
| EPS | -11 | -34 | -58 | -50 | -47 | -42 | -45 | -33 | -22 | -8.42 | -50 |
| Balance Sheet | |||||||||||
| Total Assets | 16.3M | 67.0M | 45.4M | 71.6M | 99.5M | 83.4M | 91.3M | 61.5M | 32.2M | 42.2M | 30.7M |
| Total Liabilities | 1.10M | 5.35M | 11.4M | 17.0M | 20.6M | 17.9M | 25.6M | 24.4M | 14.7M | 15.8M | 28.4M |
| Shareholders' Equity | 15.2M | 61.6M | 34.0M | 54.6M | 78.9M | 65.5M | 65.7M | 37.1M | 17.5M | 26.4M | 2.31M |
| Cash & Short-term Investments | 15.0M | 63.6M | 39.2M | 59.4M | 84.9M | 64.4M | 76.3M | 48.5M | 22.5M | 27.1M | 17.4M |
| Total Debt | - | 2.50M | - | 5.80M | 7.15M | 12.0M | 19.3M | 14.7M | 8.88M | 4.20M | 8.81M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.97M | -12.2M | -26.4M | -30.8M | -32.5M | -38.8M | -41.8M | -40.0M | -36.3M | -21.7M | -79.9M |
| Capital Expenditure | 516K | 1.20M | 1.85M | 46.4K | 595K | 913K | 171K | 0.00 | 66.0K | 177K | 242K |
| Free Cash Flow | -6.48M | -13.4M | -28.3M | -30.8M | -33.1M | -39.8M | -42.0M | -40.0M | -36.4M | -21.9M | -80.1M |
| Ratios | |||||||||||
| ROE | -50.5% | -37.7% | -114.7% | -67.2% | -56.8% | -67.4% | -80.7% | -136.8% | -232.4% | -100.6% | -13,700.9% |
| ROA | -47.0% | -34.7% | -85.9% | -51.3% | -45.0% | -53.0% | -58.1% | -82.5% | -126.4% | -63.0% | -1,030.7% |
| Net Profit Margin | - | - | -3,411.5% | -1,061.2% | -1,419.8% | -295.6% | -4,257.8% | -924.1% | -438.0% | -96.9% | -1,166.7% |
| Debt to Equity | - | 0.04x | - | 0.11x | 0.09x | 0.18x | 0.29x | 0.40x | 0.51x | 0.16x | 3.81x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cue Biopharma dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 200K | 0.17 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:30 on Apr 24, 2026.
Who owns Cue Biopharma
- Insiders 15.05%
- Institutions 25.22%
- Public & others 59.72%
- Shares outstanding 7.26M
- Free float 6.36M
Top funds holding CUE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 233K | 3.21% | +108.27% | Sep 2026 |
| Fidelity Extended Market Index | 31.1K | 0.43% | +51.51% | Sep 2026 |
| Fidelity Total Market Index | 11.9K | 0.16% | +60.13% | Sep 2026 |
| Fidelity Series Total Market Index | 10.5K | 0.14% | +65.19% | Sep 2026 |
| iShares Micro-Cap ETF | 8.28K | 0.11% | 0.00% | Oct 2026 |
| Vanguard U.S. Eq Idx £ Acc | 2.68K | 0.04% | +63.78% | Sep 2026 |
| Vanguard Balanced Index Inv | 1.72K | 0.02% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 1.02K | 0.01% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 582.00 | 0.01% | -22.09% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 301.00 | 0.00% | 0.00% | Oct 2026 |
| JHVIT Total Stock Market Index I | 73.00 | 0.00% | +23.73% | Aug 2026 |
| Guggenheim Active Allocation Fund | 12.00 | 0.00% | 0.00% | Aug 2026 |
Top institutions holding CUE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Bleichroeder LP | 371K | 5.10% | +63.09% | Jun 2026 |
| Driehaus Capital Management LLC | 292K | 4.02% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 162K | 2.23% | +97.42% | Jun 2026 |
| Ikarian Capital, LLC | 104K | 1.44% | 0.00% | Jun 2026 |
| Polygon Management Ltd | 93.8K | 1.29% | 0.00% | Jun 2026 |
| StemPoint Capital LP | 67.0K | 0.92% | 0.00% | Jun 2026 |
| BlackRock Inc | 57.8K | 0.80% | +286.13% | Jun 2026 |
| ADAR1 Capital Management LLC | 55.2K | 0.76% | 0.00% | Jun 2026 |
| Lion Point Capital, LP | 52.9K | 0.73% | -27.91% | Jun 2026 |
| Squadron Capital Management LLC | 50.0K | 0.69% | 0.00% | Jun 2026 |
| Diadema Partners LP | 48.4K | 0.67% | +999.55% | Jun 2026 |
| Geode Capital Management, LLC | 47.8K | 0.66% | +34.77% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 31.5K | 0.43% | 0.00% | Jun 2026 |
| UBS Group AG | 26.7K | 0.37% | +806.62% | Jun 2026 |
| Citadel Advisors Llc | 25.6K | 0.35% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 24.5K | 0.34% | +35.09% | Jun 2026 |
| Texas Capital Bank Wealth Management Services Inc | 22.9K | 0.32% | +72.74% | Jun 2026 |
| Renaissance Technologies Corp | 14.7K | 0.20% | +106.10% | Jun 2026 |
| State Street Corp | 14.2K | 0.20% | +137.14% | Jun 2026 |
| Persistent Asset Partners Limited | 12.3K | 0.17% | +1,008.99% | Jun 2026 |
Cue Biopharma company profile
- Company name
- Cue Biopharma
- Ticker
- CUE.US
- Exchange
- USA Stocks
- Listed since
- Jan 2, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Fiscal year end
- December
- Address
- 40 Guest Street, Boston, MA, United States, 02135
- Phone
- 617 949 2680
- Website
- cuebiopharma.com
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Cue Biopharma management
10- Ms. Lucinda WarrenPrincipal Accounting Officer & Chief Business Officer · born 1969
- Mr. Colin G. Sandercock J.D., MSESenior Vice President of Intellectual Property · born 1957
- Dr. Shao-Lee Lin M.D., Ph.D.President, CEO & Director · born 1967
- Dr. Ronald D. Seidel III, Ph.D.Co-Founder · born 1976
- Dr. Rodolfo Jose Chaparro Ph.D.Co-Founder · born 1973
- Dr. Steven C. Almo Ph.D.Co-Founder and Chairman of Scientific & Clinical Advisory Board · born 1961
- Mr. James M. AhlersChief Financial Officer · born 1964
- Ms. Agnes LeeChief Officer of Public & Investor Relations
- Ms. Sumita Ray J.D.Chief Legal & Compliance Officer and Corporate Secretary · born 1974
- Dr. Daniel G. Baker M.D., Ph.D.Interim Chief Development Officer · born 1950